This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F11%3A00002688%21RIV12-MZ0-00023001/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F11%3A00002688%21RIV12-MZ0-00023001
rdf:type
skos:Concept n11:Vysledek
dcterms:description
The aortic valve treatment revolution continues with the maturation of aortic valve repair and the dissemination of transcatheter aortic valve implantation. The recent publication of comprehensive multidisciplinary guidelines for diseases of the thoracic aorta has assigned important roles for the cardiovascular anesthesiologist and perioperative echocardiographer. Although intense angiotensin blockade improves outcomes in heart failure, it might further complicate the maintenance of perioperative systemic vascular tone. Ultrafiltration as well as intensive medical management guided by the biomarker brain natriuretic peptide improves outcomes in heart failure. Continuous-flow left ventricular assist devices have further improved outcomes in the surgical management of heart failure. Major risk factors for bleeding in the setting of these devices include advanced liver disease and acquired von Willebrand syndrome. The metabolic modulator perhexiline improves myocardial diastolic energetics to achieve significant symptomatic improvement in hypertrophic cardiomyopathy. A landmark report was also published recently that outlines the major areas for future research and clinical innovation in this disease. Landmark trials have documented the outcome importance of perioperative cerebral oxygen saturation monitoring as well as the outcome advantages of the Sano shunt over the modified Blalock-Taussig shunt in the Norwood procedure. Furthermore, the development and evaluation of pediatric-specific ventricular assist devices likely will revolutionize the mechanical management of pediatric heart failure. A multidisciplinary review has highlighted the priorities for future perioperative trials in congenital heart disease. These pervasive developments likely will influence the future training models in pediatric cardiac anesthesia. The aortic valve treatment revolution continues with the maturation of aortic valve repair and the dissemination of transcatheter aortic valve implantation. The recent publication of comprehensive multidisciplinary guidelines for diseases of the thoracic aorta has assigned important roles for the cardiovascular anesthesiologist and perioperative echocardiographer. Although intense angiotensin blockade improves outcomes in heart failure, it might further complicate the maintenance of perioperative systemic vascular tone. Ultrafiltration as well as intensive medical management guided by the biomarker brain natriuretic peptide improves outcomes in heart failure. Continuous-flow left ventricular assist devices have further improved outcomes in the surgical management of heart failure. Major risk factors for bleeding in the setting of these devices include advanced liver disease and acquired von Willebrand syndrome. The metabolic modulator perhexiline improves myocardial diastolic energetics to achieve significant symptomatic improvement in hypertrophic cardiomyopathy. A landmark report was also published recently that outlines the major areas for future research and clinical innovation in this disease. Landmark trials have documented the outcome importance of perioperative cerebral oxygen saturation monitoring as well as the outcome advantages of the Sano shunt over the modified Blalock-Taussig shunt in the Norwood procedure. Furthermore, the development and evaluation of pediatric-specific ventricular assist devices likely will revolutionize the mechanical management of pediatric heart failure. A multidisciplinary review has highlighted the priorities for future perioperative trials in congenital heart disease. These pervasive developments likely will influence the future training models in pediatric cardiac anesthesia.
dcterms:title
The year in cardiothoracic and vascular anesthesia: selected highlights from 2010 The year in cardiothoracic and vascular anesthesia: selected highlights from 2010
skos:prefLabel
The year in cardiothoracic and vascular anesthesia: selected highlights from 2010 The year in cardiothoracic and vascular anesthesia: selected highlights from 2010
skos:notation
RIV/00023001:_____/11:00002688!RIV12-MZ0-00023001
n11:predkladatel
n12:ico%3A00023001
n3:aktivita
n13:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n6:2012
n3:domaciTvurceVysledku
n14:3523314
n3:druhVysledku
n15:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
242038
n3:idVysledku
RIV/00023001:_____/11:00002688
n3:jazykVysledku
n7:eng
n3:klicovaSlova
aortic valve; aortic valve repair; transcatheter aortic valve implantation; thoracic aorta; guidelines; endovascular aortic repair; aortic dissection; aortic aneurysm; heart failure; ventricular assist device; angiotensin; ultrafiltration; natriuretic peptide; model for end-stage liver disease; von Willebrand syndrome; hypertrophic cardiomyopathy; perhexiline; metabolic modulator; cerebral oxygen saturation; near-infrared; spectroscopy; Norwood procedure; Sano shunt; Blalock-Taussig shunt; congenital heart disease; perioperative management
n3:klicoveSlovo
n5:guidelines n5:hypertrophic%20cardiomyopathy n5:aortic%20aneurysm n5:aortic%20valve%20repair n5:thoracic%20aorta n5:perioperative%20management n5:aortic%20valve n5:model%20for%20end-stage%20liver%20disease n5:aortic%20dissection n5:near-infrared n5:perhexiline n5:Blalock-Taussig%20shunt n5:Norwood%20procedure n5:natriuretic%20peptide n5:von%20Willebrand%20syndrome n5:heart%20failure n5:metabolic%20modulator n5:transcatheter%20aortic%20valve%20implantation n5:cerebral%20oxygen%20saturation n5:congenital%20heart%20disease n5:Sano%20shunt n5:spectroscopy n5:endovascular%20aortic%20repair n5:ultrafiltration n5:angiotensin n5:ventricular%20assist%20device
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[F61D3A2C5D63]
n3:nazevZdroje
Journal of cardiothoracic and vascular anesthesia
n3:obor
n10:FP
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
11
n3:rokUplatneniVysledku
n6:2011
n3:svazekPeriodika
25
n3:tvurceVysledku
Augoustides, JGT Ramakrishna, H. Sinha, A. Patel, P. Roscher, C. Říha, Hynek Singh, N. Wyckoff, T. Subramaniam, B. Fassl, J. Andritsos, M.
n3:wos
000287065200003
s:issn
1053-0770
s:numberOfPages
10